The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
Abstract
The tumor-associated antigen MUC1 is overexpressed on various hematological and epithelial malignancies and is therefore a suitable candidate for broadly applicable vaccine therapies. It was demonstrated that major histocompatibility complex (MHC)-unrestricted cytotoxic T cells can recognize epitopes of the MUC1 protein core localized in the tandem repeat domain. There is increasing evidence now that MHC-restricted T cells can also be induced after immunization with the MUC1 protein or segments of the core tandem repeat. Using a computer analysis of the MUC1 amino acid sequence, we identified two novel peptides with a high binding probability to the HLA-A2 molecule. One of the peptides is derived from the tandem repeat region and the other is derived from the leader sequence of the MUC1 protein, suggesting that, in contrast to previous reports, the MUC1-directed immune responses are not limited to the extracellular tandem repeat domain. Cytotoxic T cells (CTL) were generated from several healthy donors by primary in vitro immunization using peptide-pulsed dendritic cells. The addition of a Pan-HLA-DR binding peptide PADRE as a T-helper epitope during the in vitro priming resulted in an increased cytotoxic activity of the MUC1-specific CTL and a higher production of cytokines such as interleukin-12 and interferon-γ in the cell cultures, demonstrating the importance of CD4 cells for an efficient CTL priming. The peptide induced CTL lysed tumors endogenously expressing MUC1 in an antigen-specific and HLA-A2–restricted fashion, including breast and pancreatic tumor cells as well as renal cell carcinoma cells, showing that these peptides are shared among many tumors. The use of MUC1-derived peptides could provide a broadly applicable approach for the development of dendritic cell-based vaccination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Origin, maturation and antigen presenting function of dendritic cells
Cella, M., Sallusto, F., & Lanzavecchia, A. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80153-7 · Cited by 1,320
Romani, N., Reider, D., Heuer, M., Ebner, S., Kämpgen, E., Eibl, B., Niederwieser, D., & Schuler, G. (1996) · Journal of Immunological Methods · doi:10.1016/0022-1759(96)00078-6 · Cited by 1,091
CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
Zhou, L. J., & Tedder, T. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2588 · Cited by 1,067
The Biochemistry and Cell Biology of Antigen Processing and Presentation
Germain, R. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.403 · Cited by 1,020
Signals and signs for lymphocyte responses
Janeway, C. A., & Bottomly, K. (1994) · Cell · doi:10.1016/0092-8674(94)90335-2 · Cited by 848
Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.87 · Cited by 828
Peptides Naturally Presented by MHC Class I Molecules
Rammensee, H. G., Falk, K., & Rötzschke, O. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001241 · Cited by 799
Self-citationPeptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., & Burchell, J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37632-4 · Cited by 568
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A., et al. (1994) · Immunity · doi:10.1016/s1074-7613(94)80017-0 · Cited by 523
HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation
Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546329 · Cited by 520
Barnd, D. L., Lan, M. S., Metzgar, R. S., & Finn, O. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7159 · Cited by 449
Porgador, A., & Gilboa, E. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.255 · Cited by 362
Differentiation of human dendritic cells from monocytes in vitro
Chapuis, F., Rosenzwajg, M., Yagello, M., Ekman, M., Biberfeld, P., & Gluckman, J. C. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270213 · Cited by 338
MHC Ligands and Peptide Motifs
Rammensee, H.-G., Bachmann, J., & Stevanović, S. (1997) · Molecular Biology Intelligence Unit · doi:10.1007/978-3-662-22162-4 · Cited by 331
Self-citationGirling, A. C., Bártková, J., Burchell, J., Gendler, S. J., Gillett, C., & Taylor-Papadimitriou, J. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430620 · Cited by 330
Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., & Finn, O. J. (1994) · PubMed · Cited by 311
Generation of Mature Dendritic Cells from Human Blood
Schuler, G., & Romani, N. (1997) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4757-9966-8_2 · Cited by 309
Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.
Siddiqui, J., Abe, M., Hayes, D., Shani, E., Yunis, E., & Kufe, D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2320 · Cited by 308
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
Agrawal, B., Krantz, M. J., Reddish, M. A., & Longenecker, B. M. (1998) · Nature Medicine · doi:10.1038/nm0198-043 · Cited by 294
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S., & Bevan, M. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3270 · Cited by 264
Self-citationKaranikas, V, Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V, Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119825 · Cited by 263
MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines
Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magarian‐Blander, J., & Barratt‐Boyes, S. M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00077.x · Cited by 261
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
Brossart, P., Stuhler, G., Flad, T., Stevanović, S., Rammensee, H., Kanz, L., & Brugger, W. (1998) · PubMed · Cited by 223
Self-citationBrossart, P., & Bevan, M. J. (1997) · Blood · doi:10.1182/blood.v90.4.1594 · Cited by 200
Self-citationJerome, K. R., Domenech, N., & Finn, O. J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1654 · Cited by 175
Antigen presentation to cytotoxic T lymphocytes in vivo.
Bevan, M. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.639 · Cited by 163
Kobayashi, H., Terao, T., & Kawashima, Y. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.95 · Cited by 160
Doménech, N., Henderson, R. A., & Finn, O. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.10.4766 · Cited by 155
Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen
Apostolopoulos, V., Karanikas, V., Haurum, J. S., & McKenzie, I. F. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5211 · Cited by 147
Cellular Mucins: Targets for Immunotherapy
Apostolopoulos, V., & McKenzie, I. F. C. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v37.i2-6.110 · Cited by 136
Dendritic Cells: Antigen Presentation, Accessory Function and Clinical Relevance
Steinman, R. M., Witmer-Pack, M. D., & Inaba, K. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2930-9_1 · Cited by 116
Cellular Mucins: Targets for Immunotherapy
Apostolopoulos, V., & McKenzie, I. F. C. (1994) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v14.i3-4.40 · Cited by 114
An empirical method for the prediction of T-cell epitopes
Davenport, M. P., Shon, I. A. H., & Hill, A. (1995) · Immunogenetics · doi:10.1007/bf00179401 · Cited by 70
MUC1 peptide epitopes associated with five different H‐2 class I molecules
Apostolopoulos, V., Haurum, J. S., & McKenzie, I. F. C. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271017 · Cited by 60
Cited by
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Self-citationA listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 639
Self-citationRetractedCancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Metadata
- Authors
- Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A., Rammensee, H.-G., Kanz, L., & Brugger, W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-06-15
- Volume
- 93
- Issue
- 12
- Pages
- 4309-4317
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2129537109
- Cited by
- 306
- References
- 41
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.